Acadia Pharmaceuticals Inc. · 9 hours ago
Senior Director, Portfolio Management
San Diego, CA
Full-time
Hybrid
Director/Executive
$240K/yr - $285K/yr
12+ years expAcadia Pharmaceuticals is dedicated to transforming scientific advancements into innovative treatments for underserved communities affected by neurological and rare diseases. The Senior Director of Portfolio Management will be instrumental in shaping the strategic direction of the company's development and commercialization portfolio, ensuring alignment with financial viability and market opportunities through collaboration with key stakeholders across Finance, R&D, and Commercial.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Lead the development and implementation of portfolio prioritization frameworks that balance scientific innovation, commercial potential, and financial impact
Partner closely with Finance to assess investment scenarios, optimize resource allocation, and ensure portfolio decisions are grounded in financial rigor
Collaborate with R&D leadership to align pipeline strategy with portfolio goals, ensuring scientific feasibility and milestone-driven execution
Engage with Commercial teams to incorporate market insights, competitive intelligence, and launch readiness into portfolio planning
Facilitate governance processes that promote transparency, agility, and accountability across the portfolio lifecycle
Drive continuous improvement in portfolio operations, leveraging data and analytics to inform strategic decisions and enhance execution efficiency
Lead focused initiatives supporting continuous improvement of Acadia’s Portfolio Governance and Operating Model
Serve as a trusted advisor to Portfolio Governance (PG), providing clear, actionable insights on portfolio performance, trade-offs, and strategic risks
Champion a culture of accountability, collaboration, and innovation across teams and functions
Other responsibilities as assigned
Qualification
Required
Bachelor's degree in life science or related field; Advanced degree preferred
Targeting 12 years of progressively responsible, relevant experience focusing on program management with 8 years in a leadership role which includes experience managing cross-functional project teams
Strong understanding of the drug development process from preclinical pharmacology through to regulatory approval
Principles, concepts, practices, and standards of pharmaceutical program management
Significant amount of experience required in portfolio management, strategic planning, or program leadership within the biotech or life sciences industry
Proven ability to lead cross-functional teams and influence senior stakeholders in a matrixed environment
Strong understanding of drug development processes, commercialization strategies, and financial modeling
Executive presence and exceptional communication, analytical, and problem-solving skills
Advanced meeting facilitation skills and ability to lead cross-functional teams that include executive and senior management without direct authority
Ability to elicit cooperation from a wide variety of sources and to be persuasive, encouraging and motivating
In-depth knowledge and skill with Microsoft (MS) suite including MS PowerPoint, MS Project, MS Word, MS Excel
Must be able and willing to travel on occasion
Preferred
Experience with governance frameworks and enterprise operating models is highly desirable
Benefits
Medical, dental, and vision insurance
Employer-paid life, disability, business travel and EAP coverage
401(k) Plan with a fully vested company match 1:1 up to 5%
Employee Stock Purchase Plan with a 2-year purchase price lock-in
15+ vacation days
13 -15 paid holidays, including office closure between December 24th and January 1st
10 days of paid sick time
Paid parental leave benefit
Tuition assistance
Company
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$811.73MKey Investors
National Institute of Neurological Disorders and StrokeOxford Bioscience PartnersNational Institute of Mental Health
2019-09-17Post Ipo Equity· $287.5M
2018-11-30Post Ipo Equity· $316.25M
2013-01-02Post Ipo Equity· $86.39M
Leadership Team
Catherine Adams
Chief Executive Officer
Steve Davis
President and CEO
Recent News
Company data provided by crunchbase